FL-ZYCUS
20.5.2024 15:01:27 CEST | Business Wire | Press release
Zycus, the pioneer in Generative AI-powered Source-to-Pay solutions, ignited a wave of innovation at its annual procurement conference, Horizon 2024. The event showcased a groundbreaking suite of GenAI advancements designed to elevate automation, intelligence, and efficiency throughout the Source-to-Pay (S2P) process.
Zycus Revolutionizes Procurement with Merlin
Zycus introduced a two-pronged approach to GenAI-powered procurement:
- Merlin Assist Chatbot: Integrated with Microsoft Teams, this AI assistant acts as the "front door" to procurement, allowing users to ask questions, extract contract details, generate summaries, develop strategies, and streamline workflows—all within the familiar Teams environment. As we say at Zycus, AI is the new UI.
- Merlin GenAI Power Apps: Delivered through AppXtend, these applications unlock 10x efficiency and effectiveness, addressing critical tasks such as streamlining approvals, automating contract risk management, simplifying sourcing, enhancing Accounts Payable, automating project management, facilitating supplier risk management, and validating reports with Insight Studio.
"Zycus' Merlin GenAI addresses critical pain points across the S2P process, surpassing basic automation like invoice processing or user assignment," said the Head of Indirect Procurement of a Global 500 company at Horizon.
Aatish Dedhia, Founder & CEO of Zycus, highlighted, "With over 20 years of AI-driven innovation including five years with the Merlin AI platform, Zycus has built deep, well-managed datasets, ensuring effective GenAI model training and a nuanced understanding of customer needs. Our AppXtend API framework enables rapid development, deployment, and deep integration of GenAI across S2P processes.”
Industry Validation: Microsoft Recognizes Zycus Leadership
"AI will transform the way individuals, teams, and organizations work," said Samik Roy, Executive Director, Corporate, Medium and Small Businesses, Microsoft India. "Zycus has integrated Azure OpenAI to infuse AI into its daily operations. The quantitative impact is very encouraging. From personalized experiences to streamlined workflows, AI will start becoming the cornerstone of Zycus's success."
Zycus Horizon: A Springboard for GenAI Leadership
Horizon 2024 served as a powerful platform for Zycus to demonstrate its leadership in GenAI-powered procurement solutions, empowering businesses with significant efficiency gains, agility, cost savings, and a competitive advantage.
About Zycus:
Zycus is the leader in Source-to-Pay (S2P) solutions, pioneering the world's first Generative AI powered platform that helps procurement achieve 10X speed and efficiency. It has been a trusted partner of choice for large global enterprises and is consistently recognized by leading analysts like Gartner and Forrester.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520570248/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom